Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE).
Chiara Lazzari
No relevant relationships to disclose
Silvia Novello
No relevant relationships to disclose
Sandro Barni
No relevant relationships to disclose
Michele Aieta
No relevant relationships to disclose
Filippo De Marinis
No relevant relationships to disclose
Tommaso De Pas
No relevant relationships to disclose
Francesco Grossi
No relevant relationships to disclose
Manlio Mencoboni
No relevant relationships to disclose
Alessandra Bearz
No relevant relationships to disclose
Irene Floriani
No relevant relationships to disclose
Valter Torri
No relevant relationships to disclose
Alessandra Bulotta
No relevant relationships to disclose
Julia Grigorieva
Employment or Leadership Position - Biodesix
Stock Ownership - Biodesix
Research Funding - Biodesix
Joanna Roder
Employment or Leadership Position - Biodesix (B)
Stock Ownership - Biodesix (B)
Claudio Doglioni
No relevant relationships to disclose
Heinrich Roder
Employment or Leadership Position - Biodesix (B)
Stock Ownership - Biodesix (B)
Luisella Righi
No relevant relationships to disclose
Silvia Foti
No relevant relationships to disclose
Angela Bachi
No relevant relationships to disclose
Vanesa Gregorc
No relevant relationships to disclose